Related Experiment Video
Updated: Jan 23, 2026

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
Published on: September 1, 2023
Urokinase Plasminogen Activator Deficiency Delays the Development of Obesity and Metabolic Sequelae
Woosuk S Hur1, Yesha N Patel1, Sara R Abrahams1
1Department of Pathology and Laboratory Medicine, Blood Research Center, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (W.S.H., Y.N.P., S.R.A., H.E.H., A.T.J., O.A.N., A.S.W., M.J.F.).
Background:
Obesity predisposes individuals to multiple pathologies, including metabolic dysfunction-associated steatotic liver disease and diabetes. Although it is known that accumulation of proinflammatory macrophages within adipose tissues drives adiposity and provokes obesity-linked sequelae, the molecular mechanisms that provoke macrophage dysfunction in obesity remain elusive. Macrophages express high levels of uPA (urokinase plasminogen activator), and uPA has been implicated in leukocyte migration.
Methods:
Human adipose tissues from patients receiving bariatric surgery were collected and analyzed for uPA protein levels. To determine the impact of uPA in adipose tissue and subsequent high-fat diet (HFD)-induced weight gain and metabolic diseases, a novel mouse model with a conditional knockout of uPA (Plaufl/fl) was generated. PlauWT/WT, PlauKO/KO (global uPA deficiency), and Plaufl/fl/LysM Cre+ (conditional uPA deficiency in macrophages) mice were fed low-fat diet or HFD for up to 20 weeks.
Results:
Protein levels of visceral adipose tissue uPA positively correlated with body mass index in patients with obesity, and uPA levels decreased in adipose tissue 2 years after bariatric surgery. The expression and activity of uPA also increased in the adipose tissue of HFD-fed control mice. PlauKO/KO mice displayed reduced weight gain and metabolic sequelae through 14 weeks on a HFD compared with PlauWT/WT mice, but not with prolonged HFD feeding. Interestingly, Plaufl/fl/LysM Cre+ mice developed HFD-induced metabolic pathologies equivalently to PlauWT/WT mice.
Conclusions:
Our findings suggest that global uPA deletion, but not selective deletion of uPA in LysM+ myeloid cells, attenuates the development of early-stage HFD-driven obesity and pathologies consistent with metabolic syndrome.
More Related Videos
05:10Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity
What is Metabolism?
Drug Dosing: Obese Patients
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Activation Energy